3,4-Toluenediamine is a colorless to light brown solid. It is a versatile organic compound used in the synthesis of various chemicals and materials. It is an aromatic diamine with two amino groups attached to the toluene ring at the 3 and 4 positions. 3,4-Toluenediamine is a key intermediate in the production of polymers, dyes, pigments, and pharmaceuticals. It is also used as a reagent in various chemical reactions and as a starting material for the synthesis of other organic compounds. The compound is known to exhibit skin and eye irritation, and prolonged exposure can cause allergic reactions. Research on 3,4-toluenediamine focuses on understanding its properties and reactivity, developing new applications for this versatile compound, and exploring its potential environmental impact. Studies are conducted to optimize its synthesis and to investigate its use in novel materials, such as polymers and composites. Due to its potential toxicity, research also focuses on developing safer handling and disposal methods for this compound.'
3,4-toluenediamine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10332 |
| CHEMBL ID | 1319452 |
| SCHEMBL ID | 102738 |
| MeSH ID | M0057188 |
| Synonym |
|---|
| 636-24-8 |
| unii-oe7hj54p5c |
| 4-13-00-00260 (beilstein handbook reference) |
| oe7hj54p5c , |
| EN300-41268 |
| 4-methyl-1,2-diaminobenzene |
| 4-methyl-1,2-phenylenediamine |
| 3,4-diamino-1-methylbenzene |
| toluene-3,4-diamine |
| 3,4-tolylenediamine |
| nsc1495 |
| wln: zr bz d1 |
| 4-methyl-1,2-benzenediamine |
| 3,4-toluylenediamine |
| 4-methyl-o-phenylenediamine |
| 1,2-diamino-4-methylbenzene |
| 3,4-diaminotoluene |
| nsc-1495 |
| 496-72-0 |
| 3,4-toluenediamine |
| 2-amino-4-methylphenylamine |
| AC-907/25014184 |
| 1,2-benzenediamine, 4-methyl- |
| 4-methylbenzene-1,2-diamine |
| inchi=1/c7h10n2/c1-5-2-3-6(8)7(9)4-5/h2-4h,8-9h2,1h |
| NCGC00091277-01 |
| brn 0507965 |
| hsdb 6070 |
| nsc 1495 |
| ccris 4611 |
| einecs 207-826-2 |
| 3,4-diaminotoluene, 97% |
| NCGC00091277-02 |
| 3,4-diaminotoluene, 99%, purified by sublimation |
| AC-10826 |
| tolylene-3,4-diamine |
| D0125 |
| AKOS001476169 |
| smr001371992 |
| MLS002454370 |
| STK895715 |
| NCGC00091277-06 |
| NCGC00091277-05 |
| NCGC00091277-04 |
| NCGC00091277-03 |
| (2-amino-5-methyl-phenyl)-amine |
| 3,4-toluendiamine |
| HMS3039M17 |
| cas-496-72-0 |
| NCGC00259298-01 |
| tox21_201749 |
| dtxcid104930 |
| tox21_300507 |
| dtxsid9024930 , |
| NCGC00254324-01 |
| 4-methylbenzene-1,2-diamine;3,4-diaminotoluene |
| A827789 |
| BBL013178 |
| FT-0614205 |
| SCHEMBL102738 |
| toluene-3,4-diamine [inci] |
| 3,4-diaminotoluene [hsdb] |
| diaminotoluene, 3,4- |
| 3,4-toluene diamine |
| 4-methyl-benzene-1,2-diamine |
| 3,4 diamino toluene |
| 4-methyl-benzene-1, 2-diamine |
| 3,4-diaminotoluene dihydrochloride |
| W-106015 |
| STR02446 |
| CS-W013550 |
| CHEMBL1319452 |
| F0001-1293 |
| mfcd00007728 |
| 4-methyl-o-phenylenediamine, purum, >=98.0% (nt) |
| 4-methyl-o-phenylenediamine, vetec(tm) reagent grade, 97% |
| tolue- ne-3,4-diamine |
| 9ay , |
| Q26841301 |
| AMY22503 |
| D77752 |
| Z394649898 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Previously, the Cosmetic Ingredient Review Expert Panel determined that all 3 ingredients were safe for use as hair dyes." | ( Final amended report of the safety assessment of toluene-2,5-diamine, toluene-2,5-diamine sulfate, and toluene-3,4-diamine as used in cosmetics. Alan Andersen, F; Belsito, DV; Bergfeld, WF; Burnett, CL; Klaassen, CD; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW, 2010) | 0.36 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " A similar study was conducted with Dutch-Belted rabbits dosed po daily at 3, 10, 30, or 100 mg of o-toluenediamine/kg body wt/day from Days 6 through 18 of gestation." | ( Teratogenesis study of o-toluenediamine in rats and rabbits. Barbee, SJ; Becci, PJ; Knickerbocker, MJ; Reagan, EL; Wedig, JH, 1983) | 0.27 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 50.1187 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 7.9397 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342 |
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 22.3872 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 100.0000 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| BRCA1 | Homo sapiens (human) | Potency | 3.1623 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 0.0398 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.5432 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 1.6709 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 5.0119 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 19.9526 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 15.8801 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 19.2275 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743040; AID743042; AID743054; AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 14.4921 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 68.7989 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 2.8936 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 37.6642 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 3.6744 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 16.7932 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 17.1286 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079 |
| P53 | Homo sapiens (human) | Potency | 2.5119 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 12.5686 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 1.7282 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 76.3517 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 101.0220 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.4435 | 31.6228 | AID902 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 112.2020 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 8.1995 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 39.8107 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 16.8182 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 57.4246 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 5.0721 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 13.7489 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 6.3096 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 6.3096 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 6.3096 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 8.0969 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Vpr | Human immunodeficiency virus 1 | Potency | 63.0957 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 3.5481 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 9.6885 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 12.1972 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 9.6885 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 0.1883 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 19.9526 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 68.6942 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 68.6942 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||